MorphoSys AG

MOR

DE0006632003

Biotechnology & Medical Research

Real-time Estimate Tradegate Other stock markets 07:48:08 2024-05-02 am EDT			5-day change	1st Jan Change
66.08 ^EUR	-0.19%		-2.36%	+94.56%

Apr. 30	European Equities Traded in the US as American Depositary Receipts Decline	MT
Apr. 30	MorphoSys AG Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

MORPHOSYS : Gets a Neutral rating from Goldman Sachs

December 19, 2023 at 07:06 am EST

In a research note published by Rajan Sharma, Goldman Sachs gives a Neutral rating to the stock. The target price remains unchanged at EUR 17.50.

Latest news about MorphoSys AG

European Equities Traded in the US as American Depositary Receipts Decline	Apr. 30	MT
MorphoSys AG Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 30	CI
MORPHOSYS : UBS remains Neutral	Apr. 30	ZD
Novartis target Morphosys multiplies losses - takeover schedule stands	Apr. 29	DP
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Monday Trading	Apr. 29	MT
Morphosys says takeover by Novartis on course after report of drug safety concern	Apr. 29	RE
Health Care Slips on Risk Bias -- Health Care Roundup	Apr. 11	DJ
Trending : Novartis Begins Tender Offer for MorphoSys Shares	Apr. 11	DJ
Novartis: MorphoSys Board recommends tender offer	Apr. 11	CF
MorphoSys Board Supports Norvartis' Buyout Offer as Tender Period Begins	Apr. 11	MT
Morphosys management bodies recommend acceptance of Novartis takeover bid	Apr. 11	DP
Novartis begins tender offer for cancer-focused MorphoSys	Apr. 11	RE
Novartis Launches Tender Offer for Germany's MorphoSys	Apr. 11	MT
Novartis initiates tender offer for MorphoSys	Apr. 11	CF
Novartis begins tender offer for cancer-focused MorphoSys	Apr. 11	RE
MorphoSys Gets US Antitrust Approval for Proposed Acquisition by Novartis	Mar. 22	MT
Novartis' EUR2.7 Billion Purchase of MorphoSys Secures US Antitrust Clearance	Mar. 22	MT
INDEX-MONITOR: Morphosys and Bilfinger in the MDax as of today - Dax unchanged	Mar. 18	DP
MorphoSys AG(XTRA:MOR) added to Germany MDAX Index (Performance)	Mar. 17	CI
MorphoSys AG(XTRA:MOR) dropped from Germany SDAX (Total Return) Index	Mar. 14	CI
Morphosys sees no obstacle on its way under the Novartis umbrella	Mar. 14	DP
Transcript : MorphoSys AG, 2023 Earnings Call, Mar 14, 2024	Mar. 14
MorphoSys Q4 EPS, Revenue Decrease	Mar. 13	MT
Morphosys with higher loss - takeover process by Novartis going according to plan	Mar. 13	DP
MorphoSys AG Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI

MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.

Sector

Biotechnology & Medical Research

Calendar

2024-05-31 - American Society of Clinical Oncology Annual Meeting - Abstract No #6502

More about the company

Income Statement Evolution

More financial data

Ratings for MorphoSys AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

66.2 EUR

Average target price

58.71 EUR

Spread / Average Target

-11.31%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MORPHOSYS AG	+94.56%	2.66B
IQVIA HOLDINGS INC.	+0.67%	42.4B
LONZA GROUP AG	+47.02%	40.04B
CELLTRION, INC.	-6.20%	28.31B
ICON PUBLIC LIMITED COMPANY	+6.55%	24.94B
ALNYLAM PHARMACEUTICALS, INC.	-21.66%	18.96B
MEDPACE HOLDINGS, INC.	+29.96%	12.3B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.57%	11.95B
UNITED THERAPEUTICS CORPORATION	+16.03%	11.32B
BIO-TECHNE CORPORATION	-4.80%	11.55B

Other Biotechnology & Medical Research

MorphoSys AG

Equities

MOR

DE0006632003

Biotechnology & Medical Research

MORPHOSYS : Gets a Neutral rating from Goldman Sachs

Latest news about MorphoSys AG

Chart MorphoSys AG

Company Profile

Income Statement Evolution

Ratings for MorphoSys AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research